Immunovant, Inc. — Director's Dealing 2019

Dec 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2019-12-18

Reporting Person: Yanchik Connealy Pamela (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-18	Stock Option (right to buy)	$8.43	A	433588	Acquired	2029-11-19	Common Stock (433588)	Direct

Footnotes

F1: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.

F2: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 886,563 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).